Amerikanische Gesellschaft für Hirudotherapie

In-depth profiles of bioactive large molecules in saliva secretions of leeches determined by combining salivary gland proteome and transcriptome data

Liu Z, Tong X, Su Y, Wang D, Du X, Zhao F, Wang D, Zhao F (2019) · Journal of Proteomics · n=0

RCT-EvidenzdetailsStudienreferenz
GRADE Sehr niedrigUnzureichende Evidenz

Studienprofil

Design
integrated proteomics and transcriptomics study combining salivary-gland proteome and transcriptome datasets to characterize the bioactive composition of leech saliva (Kunming University Department of Biological Science & Technology, China; Pu'er University, China)
Stichprobengröße (n)
Intervention
Mass-spectrometry-based proteomic analysis of leech salivary glands integrated with RNA-Seq transcriptome data; identification of 434 full-length protein sequences across the combined dataset; gene-expression analysis to identify components involved in leech sucking pathways
Komparator
Not applicable - cross-omics integration study without clinical comparator
Primärer Endpunkt
Comprehensive characterization of leech salivary bioactive proteins; identification of components implicated in leech sucking pathways; documentation that bioactive composition differs across leech species
Primäres Ergebnis
Deduced 434 full-length protein sequences from combined leech proteome and transcriptome databases; 44 proteins and 221 transcripts identified as bioactive molecules involved in leech sucking pathways; two-thirds of bioactive genes play key roles in leech bite processes; treatment efficacy may differ across leech species based on their distinct bioactive profiles; combined omics approach reveals proteins present at low concentrations that were previously uncharacterized
Follow-up-Dauer
not applicable (omics-based mechanism study)

Wichtigste Ergebnisse

  • Integrated proteomics-transcriptomics approach identified 434 full-length protein sequences in leech salivary glands
  • Documented 44 bioactive proteins plus 221 bioactive transcripts involved in leech sucking pathways
  • Established that species-level differences in bioactive composition may translate to differences in treatment efficacy
  • Demonstrated combined omics value for detecting low-abundance bioactive proteins missed by single-method approaches
  • Provides a methodological foundation for future systematic characterization of leech salivary pharmacology

Einschränkungen

  • Single-laboratory single-species study - generalizability across leech species and farms untested
  • Mechanistic omics study only - no clinical, animal, or in vivo functional validation
  • Functional annotations rely on sequence homology rather than direct functional characterization
  • Detection limits of proteomics may have missed additional low-abundance bioactives
  • No direct linkage to specific clinical indications

Klinische Implikationen

Liu 2019 provides the methodological foundation for systematic characterization of leech salivary pharmacology by combining proteomics and transcriptomics. For ASH editorial purposes, the trial is essential context for understanding why whole-leech therapy produces complex multi-target effects that cannot be replicated by any single recombinant compound. For US clinicians, the trial does not change practice but supports the editorial position that comprehensive omics-based characterization is needed before purified-compound substitutes can replace whole-leech device therapy. The cross-species variation documented here is consistent with later discoveries of HSTX peptides (Wang 2018), HLF variants (Müller 2016, Ahmed 2024), and decorsins (Tolksdorf 2025).

Verwandte Studien

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Freigabe für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.